Name: UMIN ID:
Unique ID issued by UMIN | UMIN000020601 |
---|---|
Receipt number | R000023778 |
Scientific Title | A phase II study of Nivolumab for relapsed/refractory adult T-cell leukemia/lymphoma (ATL) |
Date of disclosure of the study information | 2016/01/17 |
Last modified on | 2022/11/12 16:06:28 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2016/01/17 11:17:50 | ||
2 | Update | 2016/07/17 09:10:50 | Name of primary person or sponsor Organization Organization Institutions |
|
3 | Update | 2016/09/05 12:12:54 | Institutions |
|
4 | Update | 2017/10/03 21:41:54 | Key inclusion criteria Key inclusion criteria |
|
5 | Update | 2017/10/03 21:47:36 | Organization Organization Last name of contact person Last name of contact person Organization Organization Organization Organization Institute Organization Organization Category of Funding Organization Organization1 Institutions |
|
6 | Update | 2019/01/19 14:14:26 | Recruitment status |
|
7 | Update | 2019/07/20 22:30:08 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Division name Organization Organization Address Address Tel Institutions |
|
8 | Update | 2020/01/20 23:04:06 | Recruitment status Date of IRB Last follow-up date |
|
9 | Update | 2022/06/01 17:42:09 | Target sample size |
|
10 | Update | 2022/07/23 09:52:44 | Last follow-up date |
|
11 | Update | 2022/11/12 16:06:29 | Recruitment status |